emtricitabine--tenofovir-disoproxil-fumarate-drug-combination and Communicable-Diseases

While health care providers have largely turned a blind eye, the cost of health care in the US has been skyrocketing, in part as a result of rising drug prices. Patent protections and market exclusivity, while serving to incentivize targeted new drug development, have exacerbated inequitable outcomes and reduced access, sometimes fueling national epidemics. Branded drug manufacturers face few barriers to exorbitant pricing of drugs with exclusivity-as in the cases of Sovaldi, Zyvox, and Truvada. Furthermore, albendazole, pyrimethamine, and penicillin demonstrate that generic medications without patent exclusivity are not guaranteed to have durably low costs, especially where manufacturer competition is lacking. There is a way forward: through education and awareness, cost-conscious guideline development, government regulation, and market-level incentives, health care providers can collaborate to contain drug prices, curbing expenditures overall while expanding health care access to patients.

Topics: Albendazole; Communicable Diseases; Costs and Cost Analysis; Drug Costs; Drug Industry; Drugs, Generic; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Government Regulation; Health Expenditures; Humans; Linezolid; Penicillins; Pyrimethamine; Sofosbuvir